Skip to main content
Top
Published in: Rheumatology International 12/2012

01-12-2012 | Original Article

Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis

Authors: Fang Chen, Dongxue Wang, Xiaoming Shu, Ran Nakashima, Guochun Wang

Published in: Rheumatology International | Issue 12/2012

Login to get access

Abstract

The aim of this study is to determine serum anti-melanoma differentiation-associated gene 5 prevalence and their clinical associations in Chinese patients with polymyositis and dermatomyositis (PM/DM). Serum anti-MDA5 antibody was detected by ELISA in 113 adult PM/DM patients and in various controls. Flow cytometry was applied to analyze the subgroups of lymphocytes in the peripheral blood of PM/DM patients. The serum anti-MDA5-positive rate in the DM patients (22.6%) was significantly higher compared with that in PM patients (0%, P < 0.005), patients with SLE (3.3%, P < 0.05), RA (3.3%, P < 0.05), pSS (0%, P < 0.05), pulmonary infection (0%, P < 0.05) and healthy controls (0%, P < 0.001). The percentage of decreased CD4+, CD8+ T cell counts, raised CD4+/CD8+ ratio in peripheral blood and the incidence of acute/subacute interstitial pneumonia (A/SIP) were significantly higher in anti-MDA5-positive DM group than negative group (all P < 0.05). Additionally, logistic multivariate analysis showed that anti-MDA5 is an independent risk factor for death of ILD in DM (OR = 8.46, 95% CI 1.77–40.36, P = 0.007). In conclusion, in Chinese PM/DM patients, serum anti-MDA5 antibody is mainly presented in DM patients and can be a useful marker for A/SIP in patients with DM. It can predict unfavorable prognosis in DM patients with ILD. Further studies are needed to identify how the abnormal T cells in peripheral blood participated in the generation of the anti-MDA5 antibody.
Literature
1.
go back to reference Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–190PubMedCrossRef Rider LG, Miller FW (2011) Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 305(2):183–190PubMedCrossRef
2.
go back to reference Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine LK, Danoff S, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119PubMedCrossRef Saketkoo LA, Ascherman DP, Cottin V, Christopher-Stine LK, Danoff S, Oddis CV (2010) Interstitial lung disease in idiopathic inflammatory myopathy. Curr Rheumatol Rev 6(2):108–119PubMedCrossRef
3.
go back to reference Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32(9):1719–1726PubMed Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M et al (2005) Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32(9):1719–1726PubMed
4.
go back to reference Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T et al (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28(5):1005–1012PubMedCrossRef Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T et al (2006) Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J 28(5):1005–1012PubMedCrossRef
5.
go back to reference Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al (2009) Clinical differences between interstitial lung diseases associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136(5):1341–1347PubMedCrossRef Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S et al (2009) Clinical differences between interstitial lung diseases associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 136(5):1341–1347PubMedCrossRef
6.
go back to reference Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576PubMedCrossRef Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T et al (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576PubMedCrossRef
7.
go back to reference Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of the two parts). N Engl J Med 292(7):344–347PubMedCrossRef Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of the two parts). N Engl J Med 292(7):344–347PubMedCrossRef
8.
go back to reference Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636PubMedCrossRef Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine’ myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636PubMedCrossRef
9.
go back to reference American Thoracic Society (2006) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European respiratory society (ERS). Am J Respir Crit Care Med 161(2):646–664 American Thoracic Society (2006) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American thoracic society (ATS), and the European respiratory society (ERS). Am J Respir Crit Care Med 161(2):646–664
10.
go back to reference Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef Tan EM (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef
11.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324PubMedCrossRef
12.
go back to reference Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCrossRef Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61(6):554–558PubMedCrossRef
13.
go back to reference Kuwana M, Kimura K, Kawakami Y (2002) Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 46(10):2742–2747PubMedCrossRef Kuwana M, Kimura K, Kawakami Y (2002) Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: application to enzyme-linked immunosorbent assay. Arthritis Rheum 46(10):2742–2747PubMedCrossRef
14.
go back to reference Sato S, Hoshino K, Satoh T, Suwa A, Hirakata M, Inada S et al (2008) MDA5 (melanoma-differentiation associated gene as an autoantigen recognised by anti-CADM-140 antibody in patients with clinically amyopathic dermatomyositis (abstract). Arthritis Rheum 58:S923CrossRef Sato S, Hoshino K, Satoh T, Suwa A, Hirakata M, Inada S et al (2008) MDA5 (melanoma-differentiation associated gene as an autoantigen recognised by anti-CADM-140 antibody in patients with clinically amyopathic dermatomyositis (abstract). Arthritis Rheum 58:S923CrossRef
15.
go back to reference Sato S, Hoshino K, Satoh T, Kawakami Y, Fujita T (2009) RNA helicase encoded by melanoma differentiation—associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum 60(7):2193–2200PubMedCrossRef Sato S, Hoshino K, Satoh T, Kawakami Y, Fujita T (2009) RNA helicase encoded by melanoma differentiation—associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis. Arthritis Rheum 60(7):2193–2200PubMedCrossRef
16.
17.
go back to reference Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205(7):1601–1610PubMedCrossRef Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K et al (2008) Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med 205(7):1601–1610PubMedCrossRef
18.
go back to reference Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-c antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49(9):1726–1733PubMedCrossRef Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T (2010) Anti-MDA5 and anti-TIF1-c antibodies have clinical significance for patients with dermatomyositis. Rheumatology 49(9):1726–1733PubMedCrossRef
19.
go back to reference Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49(3):433–440PubMedCrossRef Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T et al (2010) The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology 49(3):433–440PubMedCrossRef
20.
go back to reference Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34PubMedCrossRef Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L (2011) The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 65(1):25–34PubMedCrossRef
21.
go back to reference Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee E et al (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223–231PubMedCrossRef Kang EH, Nakashima R, Mimori T, Kim J, Lee YJ, Lee E et al (2010) Myositis autoantibodies in Korean patients with inflammatory myositis: anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis. BMC Musculoskelet Disord 11:223–231PubMedCrossRef
22.
go back to reference Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17(6):701–706PubMedCrossRef Fathi M, Lundberg IE (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 17(6):701–706PubMedCrossRef
23.
go back to reference Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18(6):462–467PubMedCrossRef Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M et al (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18(6):462–467PubMedCrossRef
24.
go back to reference Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49(9):1713–1719PubMedCrossRef Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K et al (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 49(9):1713–1719PubMedCrossRef
25.
go back to reference Takada T, Suzuki E, Nakano M, Kagamu H, Tsukada H, Hasegawa T et al (1998) Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med 37(8):669–673PubMedCrossRef Takada T, Suzuki E, Nakano M, Kagamu H, Tsukada H, Hasegawa T et al (1998) Clinical features of polymyositis/dermatomyositis with steroid-resistant interstitial lung disease. Intern Med 37(8):669–673PubMedCrossRef
26.
go back to reference Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S et al (2007) Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 26(3):436–439PubMedCrossRef Miyazaki E, Ando M, Muramatsu T, Fukami T, Matsuno O, Nureki S et al (2007) Early assessment of rapidly progressive interstitial pneumonia associated with amyopathic dermatomyositis. Clin Rheumatol 26(3):436–439PubMedCrossRef
27.
go back to reference Yokoyama T, Sakamoto T, Shida N, Kinoshita M, Kunou Y, Karukaya R et al (2005) Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intens Care Med 20(3):160–163CrossRef Yokoyama T, Sakamoto T, Shida N, Kinoshita M, Kunou Y, Karukaya R et al (2005) Fatal rapidly progressive interstitial pneumonitis associated with amyopathic dermatomyositis and CD8 T lymphocytes. J Intens Care Med 20(3):160–163CrossRef
Metadata
Title
Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis
Authors
Fang Chen
Dongxue Wang
Xiaoming Shu
Ran Nakashima
Guochun Wang
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2323-y

Other articles of this Issue 12/2012

Rheumatology International 12/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.